Better Health for All

Immutep's core business is developing immunotherapies for cancer and autoimmune diseases, with 100% of its pipeline dedicated to addressing high unmet medical needs in conditions like non-small cell lung cancer, head and neck cancer, breast cancer, ulcerative colitis, and psoriasis.

Its lead product, eftilagimod alfa, is in Phase III trials for cancer, aiming to establish new standards of care and extend patient survival. The company's R&D expenses were A$61.41 million in FY2025, while its total revenue/income was A$10.33 million, indicating that over 25% of its budget is allocated to health improvement. Clinical trials, such as TACTI-004, are randomized, double-blind, multinational studies across 27 countries, enrolling approximately 756 patients, and are registered on clinicaltrials.gov. However, the global clinical trial industry's carbon footprint is estimated between 37 and 100 megatons of CO2e annually, with patient and Clinical Research Associate travel accounting for 21% of this footprint, indicating significant health externalities.

Fair Money & Economic Opportunity

Immutep Limited is a biotechnology company focused on developing immunotherapy products, not a financial institution.

The ethical value 'Fair Money & Economic Opportunity' and its associated KPIs are designed for companies operating in financial services, assessing aspects like lending practices, fee structures, financial inclusion initiatives, and wealth-building outcomes for consumers. As Immutep's core business lies outside of finance, there is no relevant evidence in the provided articles to score any of the KPIs against the specified rubric. Therefore, all KPIs are assigned a score of 0, indicating 'Not applicable' as per the rubric definitions for companies not in financial services.

Fair Trade & Ethical Sourcing

The provided articles do not contain specific, quantifiable evidence for any of the KPIs related to Fair Trade & Ethical Sourcing.

While some articles mention general ethical standards or policies, they lack concrete data points such as percentages of fair-trade certified spend, supplier audit frequencies, reported incidents of forced or child labor, traceability coverage, remediation speeds, or supplier diversity spend. Therefore, no KPIs can be scored based on the available information.

Honest & Fair Business

Immutep adopted a Whistleblower Policy in 2019, reviewed on December 20, 2019.

The policy encourages reporting, promotes ethical behavior, protects whistleblowers from reprisal, and allows confidential and anonymous reporting. The Audit Risk & Compliance Committee oversees its effectiveness. However, there is no explicit evidence of an independent investigation process or a dedicated hotline. The Board of Directors has four directors, with three non-executive directors who qualify as independent under ASX, NASDAQ, and SEC requirements, representing 75% of the board. The company adopted an Anti-Bribery and Corruption Policy in 2020 with a zero-tolerance stance, requiring key enablers to uphold ethical conduct and allowing audits of third-party activities related to agreements. However, there is no evidence of regular training or risk assessments. While third-party entities like WuXi Biologics and Labor LS hold ISO 14001 certifications, there is no explicit mention of broad independent verification of Immutep's own ethical claims or compliance.

Kind to Animals

Immutep Limited engages in animal testing, including preclinical tests and in vivo studies in non-human primate models, as required by governmental bodies and authorities for therapeutic evaluation.

The company states it follows the 3R principles (Replace, Reduce, Refine) for animal testing in therapeutic development and aims to keep in vivo studies to an absolute minimum. Immutep has introduced an animal welfare policy and agrees to comply with all relevant statutes, legislation, regulations, and guidelines for the care, welfare, and ethical treatment of animals used in research.

Planet-Friendly Business

Immutep Limited has not provided specific quantitative data on its environmental performance.

The company acknowledges the importance of ESG principles and states a future intention to conduct a GHG assessment. Water usage is considered immaterial at this time. While some suppliers, such as WuXi Biologics and Labor LS, have environmental management systems (EMS) in place and ISO 14001 certification, and WuXi Biologics' Mashan site is recognized as a Two-Star Green Factory, there is no data on the company's own emissions, renewable energy use, waste diversion, or other key environmental metrics. No environmental compliance violations were reported by WuXi Biologics in 2022, and Clinigen, another supplier, reduced CO2e emissions by 62.7% in FY2021. However, these supplier-specific data points do not apply to Immutep's overall performance for the respective KPIs.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points or actions related to Immutep Limited's engagement with local or indigenous communities, cultural impact assessments, or cultural preservation efforts. Information regarding formal partnerships, revenue reinvested locally, cultural appropriation incidents, local employment ratios, or cultural site protection is not available.

The reports primarily focus on financial performance, clinical trial progress, and internal employee diversity metrics.

Safe & Smart Tech

The company's privacy policy explicitly states that users can access, update, or delete their data, and mentions rights to rectification, objection, restriction, and data portability.

The company trains EU employees on GDPR principles and its privacy policy explicitly mentions GDPR compliance. There are no documented data breaches or incidents of unauthorized data use. However, the articles do not provide specific details on data retention periods beyond general necessity, nor do they offer quantitative data on cybersecurity investment, security training effectiveness, or privacy certifications for the company itself.